Molecular Pathology
Browse by
Recent submissions
-
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification
(AMER SOC HEMATOLOGY, 2011-03-17)The features of 100 mixed-phenotype acute leukemias (MPALs), fulfilling WHO 2008 criteria, are documented. Myeloid and T-lineage features were demonstrated by cytoplasmic myeloperoxidase and CD3; B-lineage features were ... -
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10
(NATURE PUBLISHING GROUP, 2011-04)The European LeukemiaNet (ELN), workpackage 10 (WP10) was designed to deal with diagnosis matters using morphology and immunophenotyping. This group aimed at establishing a consensus on the required reagents for proper ... -
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
(2018-07-01)Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ... -
Breast cancer biomarkers in clinical testing: analysis of a UK NEQAS ICC & ISH database containing results from 199,300 patients.
(2018-07-31)We describe a collated dataset of results from clinical testing of breast cancers carried out between 2009 and 2016 in the UK and Republic of Ireland. More than 199,000 patient biomarker datasets, together with clinicopathological ... -
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
(2018-06-28)The genetic concept of synthetic lethality has now been validated clinically through the demonstrated efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancers in individuals with germline ... -
Breast cancer intratumor genetic heterogeneity: causes and implications
(EXPERT REVIEWS, 2012-08)There is burgeoning evidence to suggest that tumor evolution follows the laws of Darwinian evolution, whereby individual tumor cell clones harbor private genetic aberrations in addition to the founder mutations, and that ... -
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
(2012-06)Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies. Here, we investigate the mechanism that underlies this synergy. ... -
From integrative genomics to therapeutic targets.
(2013-06-05)Combinatorial approaches that integrate conventional pathology with genomic profiling and functional genomics have begun to enhance our understanding of the genetic basis of breast cancer. These methods have identified key ... -
The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
BACKGROUND: MYCN is amplified in small cell lung cancers and several pediatric tumors, including alveolar rhabdomyosarcomas and neuroblastomas. MYCN protein is known to play a key oncogenic role in both alveolar rhabdomyosarcomas ... -
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
(2018-07-13)Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) ... -
Capture Hi-C Library Generation and Analysis to Detect Chromatin Interactions.
(2018-07-06)Chromosome conformation capture (3C), coupled with next-generation sequencing (Hi-C), provides a means for deciphering not only the principles underlying genome folding and architecture, but more broadly, the role 3D ... -
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
(2018-07-31)Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER+) breast cancer, but the underlying mechanisms are largely unknown. We have identified C-terminal SRC kinase (CSK) as a critical ... -
The shieldin complex mediates 53BP1-dependent DNA repair.
(2018-08)53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini1,2. This function of 53BP1 requires interactions with PTIP3 and RIF14-9, ... -
Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System
(AMER SOC HEMATOLOGY, 2014-12-06) -
Ontogenic Growth as the Root of Fundamental Differences Between Childhood and Adult Cancer
(WILEY, 2016-03)Cancer, the unregulated proliferation of cells, can occur at any age and may arise from almost all cell types. However, the incidence and types of cancer differ with age. Some cancers are predominantly observed in children, ... -
A Global Covariance Descriptor for Nuclear Atypia Scoring in Breast Histopathology Images
(IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC, 2015-09)Nuclear atypia scoring is a diagnostic measure commonly used to assess tumor grade of various cancers, including breast cancer. It provides a quantitative measure of deviation in visual appearance of cell nuclei from those ... -
A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors
(2016-11)Clinically aggressive disease behavior is difficult to predict in men with low to intermediate clinical risk prostate cancer and methylation biomarkers may be a valuable adjunct for assessing the management of these patients. ...
RSS 1.0